Skip to sections on
- Adjuvant treatment (2:07)
- Biomarkers for immunotherapy (3:15)
Funding
This independent video interview was supported by an educational grant from Pfizer and Merck KGaA.
<< Back to the immunotherapy in advanced renal cell carcinoma hub
Advertisement